Evidence map›Paper›PMID 27773462›Full record

ReviewBlood reviews2017

NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.

Li Yu, Ling Li, L Jeffrey Medeiros, Ken H Young

Abstract readReview
In one paragraph

Review in Blood reviews, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 2 pooled it
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 104 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Jozimine AInternational journal of molecular sciences · 2024
    Article
  17. Review
  18. Review
  19. How lactate affects immune strategies in lymphoma.Frontiers in molecular biosciences · 2024
    Review
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Li YuDepartment of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA; Department of Hematology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Ling LiDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
L Jeffrey MedeirosDepartment of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA.
Ken H YoungDepartment of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA; The University of Texas Graduate School of Biomedical Science, Houston, TX, USA. Electronic address: khyoung@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USFirst Affiliated Hospital of Zhengzhou University · CNSecond Affiliated Hospital of Nanchang University · CN

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
P4 -TARGETING MULTIPLE MYELOMA BY COMBINING CDK INHIBITORS AND BCL-2 ANTAGONISTSP50CA142509 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2010 to 2014
$11.1M
Convergence of MicroRNAs and p53 Signaling in Multiple Myeloma: Environmental CoR01CA138688 · NCI · UNIVERSITY OF LOUISVILLE · PI LI, YONG · 2009 to 2017
$2.9M
MYC as a Biomarker in Aggressive Non-Hodgkin LymphomaR01CA187415 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI LI, YONG · 2015 to 2019
$2.2M
UT M.D. Anderson Cancer Center Lymphoma SPOREP50CA136411 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KWAK, LARRY W · 2009 to 2011
$1.5M
Deep Sequencing of Small Regulatory RNAs in Diffuse Large B cell LymphomaRC1CA146299 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI XIAO, CHANGCHUN · 2009 to 2010
$1000k
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA136411NCI NIH HHS P50 CA142509NCI NIH HHS R01 CA138688NCI NIH HHS R01 CA187415NCI NIH HHS RC1 CA146299
6 · The paper itself

Abstract

The NF-κB pathway, a critical regulator of apoptosis, plays a key role in many normal cellular functions. Genetic alterations and other mechanisms leading to constitutive activation of the NF-κB pathway contribute to cancer development, progression and therapy resistance by activation of downstream anti-apoptotic pathways, unfavorable microenvironment interactions, and gene dysregulation. Not surprisingly, given its importance to normal and cancer cell function, the NF-κB pathway has emerged as a target for therapy. In the review, we present the physiologic role of the NF-κB pathway and recent advances in better understanding of the pathologic roles of the NF-κB pathway in major types of lymphoid neoplasms. We also provide an update of clinical trials that use NF-κB pathway inhibitors. These trials are exploring the clinical efficiency of combining NF-κB pathway inhibitors with various agents that target diverse mechanisms of action with the goal being to optimize novel therapeutic opportunities for targeting oncogenic pathways to eradicate cancer cells.

Indexed as

Molecular Targeted TherapyAnimalsAntineoplastic AgentsBiomarkers, TumorClinical Trials as TopicGene Expression Regulation, NeoplasticHumansLeukemia, LymphoidLymphoid TissueLymphomaMutationNF-kappa BSignal TransductionTreatment OutcomeTumor MicroenvironmentAntineoplastic AgentsBiomarkers, TumorNF-kappa BApoptosisB-cell lymphomaEBVMiRNANF-κB pathwayTumor microenvironment

Identifiers

PMID27773462
PMCPMC5382109
OpenAlexW2531430052

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.